ABSTRACT
An Amendment to this paper has been published and can be accessed via a link at the top of the paper.
ABSTRACT
There is an urgent need for new antibiotics against Gram-negative pathogens that are resistant to carbapenem and third-generation cephalosporins, against which antibiotics of last resort have lost most of their efficacy. Here we describe a class of synthetic antibiotics inspired by scaffolds derived from natural products. These chimeric antibiotics contain a ß-hairpin peptide macrocycle linked to the macrocycle found in the polymyxin and colistin family of natural products. They are bactericidal and have a mechanism of action that involves binding to both lipopolysaccharide and the main component (BamA) of the ß-barrel folding complex (BAM) that is required for the folding and insertion of ß-barrel proteins into the outer membrane of Gram-negative bacteria. Extensively optimized derivatives show potent activity against multidrug-resistant pathogens, including all of the Gram-negative members of the ESKAPE pathogens1. These derivatives also show favourable drug properties and overcome colistin resistance, both in vitro and in vivo. The lead candidate is currently in preclinical toxicology studies that-if successful-will allow progress into clinical studies that have the potential to address life-threatening infections by the Gram-negative pathogens, and thus to resolve a considerable unmet medical need.
Subject(s)
Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Drug Resistance, Microbial , Gram-Negative Bacteria/drug effects , Peptidomimetics/chemistry , Peptidomimetics/pharmacology , Animals , Anti-Bacterial Agents/adverse effects , Bacterial Outer Membrane Proteins/chemistry , Bacterial Outer Membrane Proteins/genetics , Biological Products/chemistry , Drug Discovery , Drug Resistance, Microbial/drug effects , Escherichia coli Proteins/chemistry , Escherichia coli Proteins/genetics , Fluorescence , Gram-Negative Bacteria/genetics , Gram-Negative Bacteria/pathogenicity , Humans , Lipopolysaccharides/chemistry , Macrocyclic Compounds/adverse effects , Macrocyclic Compounds/chemistry , Macrocyclic Compounds/pharmacology , Male , Mice , Microbial Sensitivity Tests , Microbial Viability/drug effects , Microscopy, Electron, Transmission , Models, Molecular , Mutation , Peptidomimetics/adverse effects , Photoaffinity LabelsABSTRACT
Resistance to antiangiogenic therapy in glioblastoma (GBM) patients may involve hypoxia-induced expression of C-X-C motif chemokine receptor 4 (CXCR4) on invading tumor cells, macrophage/microglial cells (MGCs), and glioma stem cells (GSCs). We determined whether antagonizing CXCR4 with POL5551 disrupts anti-vascular endothelial growth factor (VEGF) therapy-induced glioma growth and dissemination. Mice bearing orthotopic CT-2A or GL261 gliomas received POL5551 and/or anti-VEGF antibody B20-4.1.1. Brain tissue was analyzed for tumor volume, invasiveness, hypoxia, vascular density, proliferation, apoptosis, GSCs, and MGCs. Glioma cells were evaluated for CXCR4 expression and polymorphism and POL5551's effects on CXCR4 ligand binding, cell viability, and migration. No CXCR4 mutations were identified. POL5551 inhibited CXCR4 binding to its ligand, stromal cell-derived factor-1α, and reduced hypoxia- and stromal cell-derived factor-1α-mediated migration dose-dependently but minimally affected cell viability. In vivo, B20-4.1.1 increased hypoxic foci and invasiveness, as seen in GBM patients receiving anti-VEGF therapy. Combination of POL5551 and B20-4.1.1 reduced both glioma invasiveness by 16% to 39% and vascular density compared to B20-4.1.1 alone in both glioma models. Reduced populations of GSCs and MGCs were also seen in CT-2A tumors. POL5551 concentrations, evaluated by mass spectrometry, were higher in tumors than in neighboring brain tissues, likely accounting for the results. Inhibition of CXCR4-regulated tumoral, stem cell, and immune mechanisms by adjunctive CXCR4 antagonists may help overcome antiangiogenic therapy resistance, benefiting GBM patients.
Subject(s)
Angiogenesis Inhibitors/therapeutic use , Antibodies/therapeutic use , Glioma/drug therapy , Receptors, CXCR4/antagonists & inhibitors , Vascular Endothelial Growth Factor A/immunology , Animals , Apoptosis/drug effects , Calcium/metabolism , Cell Movement/drug effects , Dose-Response Relationship, Drug , Glioma/metabolism , Glioma/pathology , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Mice , Proteins/pharmacology , Signal Transduction/drug effectsABSTRACT
The clinical development of antibiotics with a new mode of action combined with efficient pulmonary drug delivery is a priority against untreatable Pseudomonas aeruginosa lung infections. POL7001 is a macrocycle antibiotic belonging to the novel class of protein epitope mimetic (PEM) molecules with selective and potent activity against P. aeruginosa We investigated ventilator-associated pneumonia (VAP) and cystic fibrosis (CF) as indications of the clinical potential of POL7001 to treat P. aeruginosa pulmonary infections. MICs of POL7001 and comparators were measured for reference and clinical P. aeruginosa strains. The therapeutic efficacy of POL7001 given by pulmonary administration was evaluated in murine models of P. aeruginosa acute and chronic pneumonia. POL7001 showed potent in vitro activity against a large panel of P. aeruginosa isolates from CF patients, including multidrug-resistant (MDR) isolates with adaptive phenotypes such as mucoid or hypermutable phenotypes. The efficacy of POL7001 was demonstrated in both wild-type and CF mice. In addition to a reduced bacterial burden in the lung, POL7001-treated mice showed progressive body weight recovery and reduced levels of inflammatory markers, indicating an improvement in general condition. Pharmacokinetic studies indicated that POL7001 reached significant concentrations in the lung after pulmonary administration, with low systemic exposure. These results support the further evaluation of POL7001 as a novel therapeutic agent for the treatment of P. aeruginosa pulmonary infections.
Subject(s)
Anti-Bacterial Agents/pharmacology , Pseudomonas aeruginosa/drug effects , Animals , Anti-Bacterial Agents/pharmacokinetics , Cystic Fibrosis/microbiology , Lung/drug effects , Lung/microbiology , Male , Mice , Mice, Inbred C57BL , Microbial Sensitivity Tests , Pneumonia, Ventilator-Associated/microbiology , Pseudomonas Infections/microbiology , Pseudomonas aeruginosa/pathogenicity , Respiratory Tract Infections/microbiologyABSTRACT
INTRODUCTION: Nephrogenic adenoma (NA) of the bladder is a rare transitional cell tumour of the bladder in children under the age of 10 years. The objective of this study was to report our experience and review the data of the literature in order to define a coherent therapeutic approach. PATIENTS AND METHODS: We report 5 cases of NA diagnosed between 1995 and 2003 in 3 boys and 2 girls with a mean age of 6.38 years and a mean follow-up of 7.1 years. RESULTS: All patients presented a risk factor for bladder irritation. Initial symptoms were nonspecific and radiology contributed to the diagnosis in two cases. Treatment was performed by transurethral resection (3 cases) or cystotomy (2 cases). One recurrence was observed 8 years after the initial diagnosis, but no cases of malignant transformation were observed during follow-up. CONCLUSION: NA of the bladder is a benign tumour which does not predispose to malignancy. The initial treatment consisted of endoscopic resection combined with elimination of risk factors. Despite the frequency of recurrence, endoscopic surveillance does not appear to be justified. Urine cytology could contribute to the diagnosis of recurrence.
Subject(s)
Adenoma/surgery , Urinary Bladder Neoplasms/surgery , Child , Child, Preschool , Female , Humans , MaleABSTRACT
Dynamic molecular motions resulting from the folding of a flexible macrocyclic component in a Cu(I)-complexed pseudorotaxane have been evidenced by variable temperature NMR experiments. The proposed conformational changes are also supported by the X-ray crystal structures of the compounds and computational studies.
Subject(s)
Copper/chemistry , Organometallic Compounds/chemistry , Rotaxanes/chemistry , Macrocyclic Compounds/chemistry , Models, Molecular , Molecular Conformation , Motion , Stereoisomerism , TemperatureABSTRACT
Tubular colonic triplication is an extremely rare hindgut malformation, with only 2 reports in the literature to date. The present authors describe the new and unusual case of a boy born with an imperforate anus, rectovesical fistula, and 3 distinct left colons. The bladder was divided by an incomplete septum. Prenatal ultrasound suggested colonic duplication. Surgical management involved resection of the triplicated segment and posterosagittal anorectal pull through.